Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
| ▸ | NR3C1 | P04150 | 15/20 | 0.52 |
| ▸ | MGLL | Q99685 | 3/20 | 0.37 |
| ▸ | BIRC5 | O15392 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4275977 | 0.92 | NR3C1 (0.42) | KCNH2NR3C1MGLLBIRC5 | |
| SCHEMBL4283107 | 0.88 | KCNH2 (0.52) | KCNH2NR3C1MGLLBIRC5 | |
| SCHEMBL4280383 | 0.82 | NR3C1 (0.49) | NR3C1MGLL | |
| SCHEMBL4278445 | 0.81 | NR3C1 (0.43) | KCNH2NR3C1MGLLBIRC5 | |
| SCHEMBL4286574 | 0.81 | NR3C1 (0.79) | NR3C1 | |
| SCHEMBL4280365 | 0.78 | NR3C1 (0.54) | NR3C1 | |
| SCHEMBL4279148 | 0.76 | NR3C1 (0.66) | KCNH2NR3C1BIRC5 | |
| SCHEMBL4273650 | 0.76 | KCNH2 (0.48) | KCNH2NR3C1MGLLBIRC5 | |
| SCHEMBL4273240 | 0.74 | NR3C1 (0.65) | NR3C1 | |
| SCHEMBL4283375 | 0.72 | NR3C1 (0.67) | NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070060633-A1 | Glucocortioid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-03-15 | — | — | US | claimed |
| US-7622594-B2 | Glucocortioid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-7622594-B2 | Glucocortioid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-7622594-B2 | Glucocortioid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-20070060633-A1 | Glucocortioid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060633-A1 | Glucocortioid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | NR3C1, MC2R, NR3C2 | KCNH2 3456/4885NR3C1 1/4885MGLL 1618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.